Is India Winning the War Against Rising Non-Communicable Diseases? The latest health statistics paint a concerning picture: diabetes, heart disease, and cancer rates are climbing, impacting millions across the country. From rural healthcare access to the burgeoning urban health crisis, challenges remain significant. This week, we delve into the crucial initiatives underway – government policies, technological advancements in telemedicine, and the rising role of preventative healthcare – that aim to address this national health emergency. Experts weigh in on the effectiveness of current strategies and the critical need for increased public awareness campaigns targeting lifestyle diseases. Are these efforts enough? Explore Abtak.com's in-depth coverage on healthcare in India and discover the vital information you need to protect your well-being and the future of public health. Stay informed; stay healthy.
New Delhi, Sep 30 (PTI) India's drug regulator Central Drugs Standard Control Organisation (CDSCO) has approved Ozempic (semaglutide injection) manufactured by Danish pharma company Novo Nordisk for use in adults with type-2 diabetes. According to sources, Ozempic, the once-a-week injection, will be available only on a doctor's prescription. "Semaglutide Injection (Ozempic@) is indicated for the treatment of adults with Insufficiently Controlled Type 2 Diabetes Mellitus as an adjunct to Diet and Exercise," the approval by CDSCO said on September 26. The US Food and Drug Administration had approved Ozempic in 2017 for type 2 diabetes. Over time, the injection has earned reputation globally, mainly because of the benefits it provides along with weight loss benefits. PTI PLB KVK KVK
New Delhi [India], July 16 (ANI): The Indian government expressed regret on Tuesday over the reported demolition of the ancestral property of celebrated filmmaker and writer Satyajit Ray in Mymensingh, Bangladesh and expressed its willingness to extend cooperation in its restoration. "We note with profound regret that the ancestral property of noted filmmaker and litterateur Satyajit Ray in Mymensingh, Bangladesh, belonging to his grandfather and eminent litterateur, Upendra Kishor Ray Chowdhury, is being demolished," the Ministry of External Affairs said. Also Read | India Urges Bangladesh ...Read More >
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. The approved drug is indicated as an adjunct to diet and exercise to improve glycemic control in adul ...Read More >
Ahmedabad: Zydus Lifesciences has expanded its presence in the U.S. generics market with a key regulatory approval for a widely used diabetes treatment. Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. This approval enables the company to enter the U.S. market with a generic version of the drug, broadening its portfolio in a high-demand therapeutic category. With the approval, Zydus becomes eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets. This li ...Read More >
Mumbai, June 27 (SocialNews.XYZ) Bollywood actor Ayushmann Khurrana joins names such as Kamal Haasan, Ariana Grande, and Jeremy Strong at the Academy of Motion Picture Arts and Sciences this year. Ayushmann along with names such as Kamal Haasan Naomi Ackie, Gillian Anderson, Branford Marsalis, Conan O'Brien, Jimmy Kimmel, Stephen Graham, Jodie Comer and Jason Momoa are among 534 individuals who were invited to join the Academy of Motion Picture Arts & Sciences on June 26. "We are thrilled to invite this esteemed class of artists, technologists, and professionals to join the Academy," said Ac ...Read More >
A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40-50% post patent expiry. Three early movers are taking sharply different routes -- low-cost, premium, and partnerships in a high-stakes land grab. The Indian market for Glucagon-Like Peptide-1 (GLP-1) therapies is currently at an inflection point and is poised for strong expansion. The current market size for anti-obesity and diabetes GLP-1 drugs in India, as of 2025, is estimated to be between ₹1,000-1,200 cr ...Read More >
New Delhi, Jul 3 (PTI) Adopting a healthier lifestyle is more effective than using the anti-diabetes drug metformin, with the benefits persisting over 20 years later, according to a study. The US Diabetes Prevention Program, launched in 1996, enrolled 3,234 patients with prediabetes from 30 institutions across 22 states. The study aimed to compare the benefits of metformin and a lifestyle modification that included exercise and a healthy diet. Researchers from The University of New Mexico, US, found that making lifestyle changes lowered the development of diabetes by 24 per cent, while the a ...Read More >
Mumbai: Less than a month after Ozempic maker Novo Nordisk announced it is cutting its global workforce as part of a restructuring plan, the layoffs have hit Indian employees in Bengaluru. Junior- to mid-level employees across functions such as sales and marketing, as well as those in the company's global business services (GBS) hub, which works with its global teams, have been impacted, according to at least three people aware of the development. "At least 100-150 will be retrenched from the commercial unit, which largely includes sales and marketing roles. They are expected to be in junior ...Read More >
Bangalore : Emcure Pharmaceuticals Ltd., (BSE: 544210, NSE: EMCURE) has announced the price revision of its weight management drug Poviztra® (semaglutide injection) across India. The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing. As the first Indian company to exclusively distribute and commercialis ...Read More >
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjaro and smart workouts" to prepare brides to walk down the aisle. The clinic did not respond to a reques ...Read More >
New Delhi [India], August 25 (ANI): India's contract research, development, and manufacturing organisation (CRDMO) sector is emerging as one of the most dynamic growth stories in the global pharmaceutical landscape. According to a recent Jefferies India report, the country's CRDMO, which has already reached revenues of around USD 3 billion, has grown at a compound annual growth rate (CAGR) of 14 per cent over the past five years. The report highlights that India's CRDMO industry has caught the attention of global investors, with its market capitalization now standing at USD 40-50 billion. Whi ...Read More >
New Delhi [India], September 30 (ANI): The Central Drugs Standard Control Organisation (CDSCO) has approved Danish drugmaker Novo Nordisk's once-a-week injection for patients suffering from Type 2 diabetes. Also Read | Durga Puja 2025: PM Narendra Modi Participates in Durga Puja Celebrations in Delhi's CR Park on Occasion of Maha Ashtami, Prays for Everyone's Happiness and Wellbeing (See Pics). In a statement provided to ANI, Novo Nordisk has stated that Ozempic is intended for individuals with Type 2 diabetes and will be available only upon a doctor's prescription. "Ozempic is meant for pe ...Read More >
Bengaluru: Alembic Pharmaceuticals, Inc., the U.S. subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics Ltd. ("Utility") in a $12 million deal to strengthen its presence in the U.S. market. Alembic will begin the commercialization of Utility's recently FDA approved product Pivya® (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya® was approved by the FDA in April 2024. Commenting on the acquisition, Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, said: "This acquisition gives us a strategic entry into the special ...Read More >
MUMBAI, Sept 25 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world's most populous nation, a senior executive said on Thursday. "I do think there is promise for products like that (orforpligron) in India, if it does get approved," Winselow Tucker, Lilly India's president said at an event in Mumbai. Tucker, however, did not indicate when Lilly plans to launch the drug. The drugmaker ha ...Read More >
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in the potentially huge market, two sources familiar with the plans told Reuters. Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand and there is sufficient supply. More recently, Novo's India team proposed moving the launch to next year, around the same time Lilly is expected to introduce its weight-loss drug Mounjaro. In a clo ...Read More >
India Diabetes Market: By Type; By Treatment Type; By Doses Form; Route of Administration; By End User; By Distribution Channel; Supplier Landscape; 2025-2034 The India diabetes market attained a value of approximately INR 316.00 Billion in 2024. The market is projected to grow at a compound annual growth rate (CAGR) of 16.00% during the forecast period of 2025-2034, reaching an estimated value of around INR 1394.01 Billion by 2034. The rising prevalence of diabetes, driven by sedentary lifestyles, changing dietary habits, and increasing obesity rates, is contributing significantly to the mar ...Read More >
Mumbai: Emcure Pharmaceuticals has reduced the price of its weight management drug Poviztra (semaglutide injection) across India by an average of 47% across dosages in a bid to widen patient access. The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg with the highest dose priced at Rs 8,999 for a month's supply. Emcure has a marketing tie-up with the Danish innovator Novo Nordisk to distribute and commercialise a ...Read More >
READ MORE: Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL The Ozempic boom has seen a drug widely used to treat diabetes and manage obesity in adults transform into 'miracle' weight loss jab that's coveted by anyone with a few extra kilos to shed. Ozempic and other alternatives like Mounjaro and Wegovy are all different brand names for the drug semaglutide that mimics the the actions of GLP-1 - a hormone in the brain that regulates appetite ...Read More >
New Delhi, Jul 2 (PTI) The Delhi High Court on Wednesday asked the Drug Controller General of India to consult experts and relevant stakeholders in deciding a plea over drug combinations sold in the market for weight loss treatment. A bench of Chief Justice D K Upadhyaya and Justice Tushar Rao Gedela asked the petitioner to give a representation to the DGCI, which was asked to decide the matter within three months. A plea filed by Jitendra Chouksey said licenses issued for the use and sale of such drugs were not based on adequate data. In an apparent reference to the recent death of popular ...Read More >
SCHOTT, a leader in specialty glass, initiates local production of high-precision glass tubing for syringes and cartridges in Gujarat, India. This marks a significant step in India's pharmaceutical sector, aligning with the 'Make in India' initiative, enhancing SCHOTT's role in the Asian market. In a notable development in India's pharmaceutical landscape, SCHOTT has successfully commenced local production of high-precision glass tubing for syringes and cartridges at its Jambusar, Gujarat facili ...Read More >
Indian brides are turning to low-cost weight-loss injections ahead of their weddings. Freepik ShowQuick Read Summary is AI-generated, newsroom-reviewed * Soon-to-be Indian brides and grooms increasingly seek weight-loss drugs before weddings * Mounjaro is preferred over Wegovy and prescribed only for medically eligible patients * Regulators warn against misuse amid cheaper local weight-loss drug versions flooding market Did our AI summary help? Let us know. Switch To Beeps Mode Soon-to- ...Read More >
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjaro and smart workouts" to prepare brides to walk down the aisle. The clinic did not respond to a requ ...Read More >
HYDERABAD: Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. Also Read: Weight-loss drug boom: Will cheaper Ozempic generics shake up India's fitness and nutrition industry? In a social media video, Klarity offers "guided nutrition, Mounjaro and smart work ...Read More >
New Delhi, Apr 2 (PTI) Emcure Pharmaceuticals on Thursday announced a reduction in the price of its weight management drug, Poviztra, a semaglutide injection, by up to 55 per cent to expand patient access. The starting dose of Poviztra (0.25 mg) will now be available at Rs 3,999 per month (inclusive of taxes), a reduction of 55 per cent from the previous price of Rs 8,790, with the price reduction effective from April 3, 2026. Across all doses, the price of Poviztra has been reduced by an average of 47 per cent. The drug is offered in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a ma ...Read More >
New Delhi, Apr 7 (PTI) As prices tumble and generic versions of GLP-1-based weight-loss drugs flood the market, a quiet frenzy is unfolding that has doctors and authorities alarmed. Medicines that are strictly prescription-based are being bought over the counter with their use expanding beyond clinical settings, often with little medical advice. For many people eager to lose weight quickly, the promise of fast results is overshadowing concerns about safety. Important factors -- like correct dosage, possible side effects, and the need for a doctor's supervision -- are being ignored. Instead, ...Read More >
New Delhi, Apr 7 (PTI) Biocon Ltd on Tuesday announced the commercial launch of biosimilars Bosaya and Aukelso, indicated for different serious bone conditions, in the US. Bosaya (biosimilar to Prolia) and Aukelso (biosimilar to Xgeva) are now available by prescription nationwide through specialty pharmacies and healthcare providers, Biocon said in a statement. Both products have been previously approved and granted interchangeable designation by the US Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws, it added. "The US ...Read More >
New Delhi: Biocon Ltd on Tuesday announced the commercial launch of biosimilars Bosaya and Aukelso, indicated for different serious bone conditions, in the US. Bosaya (biosimilar to Prolia) and Aukelso (biosimilar to Xgeva) are now available by prescription nationwide through specialty pharmacies and healthcare providers, Biocon said in a statement. Also Read: Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas Tambe Both products have been previously approved and granted interchangeable designation by the US Food and Drug Administration in September 20 ...Read More >
AstraZeneca, Pfizer, and Eli Lilly, major players in the pharmaceutical and vaccine sectors, are drawing renewed attention as investors consider the shifting political landscape. AstraZeneca's cancer treatments, including Imfinzi and Calquence, are driving strong revenue growth, while the company plans to launch up to 24 new products by 2030. Eli Lilly, bolstered by its diabetes treatments like Mounjaro and Zepbound, has seen impressive stock gains, despite recent guidance cuts. Pfizer, although facing volatility, is a solid value investment with strong long-term potential. These companies' ro ...Read More >
New Delhi [India], August 22 (ANI): India drug regulator has alerted on the theft of multiple drug products of Novo Nordisk during transit. According to the notice issued by the Drugs Controller General of India (DCGI), Dr Rajeev Raghuvanshi, Mis Novo Nordisk has informed about a theft of its products, as mentioned below, during transit from its Bhiwandi Hub to milk route (Nagpur, Raipur, Cuttack, and Kolkata). The DCGI has also mentioned in the notice that the quality of the injectables is required to be stored at 2-8 degrees Celsius; if not handled properly, storage quality might be compro ...Read More >
India has officially approved the use of Ozempic (semaglutide), a once-a-week injection designed for adults with type 2 diabetes. Approved by the Central Drugs Standard Control Organisation (CDSCO), this drug has made headlines worldwide not just for diabetes management but also for its weight loss effects. As India faces rising rates of diabetes, Ozempic's arrival is more than just a medical update, it could influence lifestyle choices for millions.Here's all we need to know about what this new development means, its potential benefits, risks, and lifestyle implications.What exactly is Ozempi ...Read More >
New Delhi [India], June 27: Yamaha Music India has reaffirmed its commitment to social responsibility by supporting Manzil Mystics, a nonprofit organization dedicated to bringing music education to underprivileged children. This initiative, part of Yamaha's broader CSR mission, underscores the company's belief in music as a transformative force for education, empowerment, and social change. Also Read | Mounjaro vs Ozempic vs Wegovy: What's the Difference? Prices, Side Effects and Other Important Details of Diabetes Management and Weight Loss Drugs. Through the donation of high-quality instru ...Read More >